|
List of Jounal Titles
A to Z index of Journal Title. Choose a letter.
Medicine & Drug Journal
37
- New drug prospect in 2001. General remarks.
- New drug prospect in 2001. CRC activities.
- New drug prospect in 2001. Sedative hypnotic (sleeping pill).
- New drug prospect in 2001. Muscle relaxant.
- New drug prospect in 2001. Antidepressant.
- New drug prospect in 2001. Antiparkinson drug.
- New drug prospect in 2001. Antiepileptic.
- New drug prospect in 2001. Drug for hemicrania.
- New drug prospect in 2001. Antipsychotic drug.
- New drug prospect in 2001. Drug for cerebrovascular disorders.
- New drug prospect in 2001. Drug for treatment of Alzheimer disease.
- New drug prospect in 2001. Angiotensin II receptor antagonist.
- New drug prospect in 2001. Drug for tretment of cardiac insufficiency.
- New drug prospect in 2001. Calcium antagonist.
- New drug prospect in 2001. Drug for treatment of ischemic heart diseases.
- New drug prospect in 2001. Analgesic (opioid pharmaceutical).
- New drug prospect in 2001. COX-2 inhibitor.
- New drug prospect in 2001. Non-steroidal anti-inflammatory drug.
- New drug prospect in 2001. Antirheumatic drug.
- New drug prospect in 2001. Drug for treatment of osteoporosis.
- New drug prospect in 2001. Antiallergic agent and antiasthmatic drug.
- New drug prospect in 2001. Antiarrhythmic drug.
- New drug prospect in 2001. Antithrombotic and antiplatelet drug.
- New drug prospect in 2001. Drug for treatment of hyperlipidemia.
- New drug prospect in 2001. Drug for diabetes mellitus and drug for treatment of diabetic complication.
- New drug prospect in 2001. Gastrointestinal drug.
- New drug prospect in 2001. Drug for treatment of liver and pancreas diseases.
- New drug prospect in 2001. Oral antimicrobial agent.
- New drug prospect in 2001. Antimicrobial agent for injection.
- New drug prospect in 2001. Antiviral agent.
- New drug prospect in 2001. Drug for treatment of lung cancer.
- New drug prospect in 2001. Drug for treatment of prostatic cancer.
- New drug prospect in 2001. Drug for digestive cancer.
- New drug prospect in 2001. Cancer therapy adjuvant.
- New drug prospect in 2001. Therapeutic agent for hematopoietic tumor.
- New drug prospect in 2001. Drug for treatment of pollakisuria and incontinence.
- New drug prospect in 2001. Drug for treatment of menopausal syndrome.
- New drug prospect in 2001. Transfusion, nutriment, and dialysis medicine.
- New drug prospect in 2001. Contrast media.
- New drug prospect in 2001. Eye drop and nasal drop.
- New drug prospect in 2001. Other drug for external use.
- New drug prospect in 2001. Contrivance of packaging and container and pharmaceutical preparation.
- New drug prospect in 2001. Advance in recent DDS.
1
- Dermatopathy due to the chemical substance. 16. 9. Contact dermatitis due to cosmetics. (2).
- Significance of outsourcing in the drug business.
- Components which restore the antibacterial activity of .BETA. - lactam on MRSA and the action mechanism.
- Present conditions of development of new drugs based on the genome and future problems.
- Pollinosis. 1. Introduction. Natural history of cedar pollinosis.
- Pollinosis. 2. Cedar pollen scattering and atmospheric phenomena.
- Pollinosis. 3. Mechanism of the cedar pollen sensitization. Cedar pollen antigen and reactivity of T cells.
- Pollinosis. 4. Sensitization and crisis and disposition in pollinosis.
- Pollinosis. 5. Usefulness of the pollen defense device.
- Pollinosis. 6. Desensitization therapy for pollinosis.
- Pollinosis. 7. Usefulness of pharmacotherapy for pollinosis and patient QOL.
- Secondary hyperparathyroidism in the chronic renal insufficiency. 2. Present conditions of diagnosis and treatment of secondary hyperparathyroidism.
- Secondary hyperparathyroidism in the chronic renal insufficiency. 3. Mechanism of pathogenesis of secondary hyperparathyroidism.
- Secondary hyperparathyroidism in the chronic renal insufficiency. 4. Pathogenesis of secondary hyperparathyroidism. 1). Clinical features.
- Secondary hyperparathyroidism in the chronic renal insufficiency. 4. Pathophysiology of secondary hyperparathyroidism. 2). Bone tissue features.
- Secondary hyperparathyroidism in the chronic renal insufficiency. 5. Diagnosis of secondary hyperparathyroidism. Diagnosis in the general dialysis clinic.
- Secondary hyperparathyroidism in the chronic renal insufficiency. 6. Therapeutic purpose and methodology of secondary hyperparathyroidism.
- Secondary hyperparathyroidism in the chronic renal insufficiency. 7. Oral pharmacotherapy for secondary hyperparathyroidism. Limitation of oral therapy and habitat segregation of the intravenous-injection treatment.
- Secondary hyperparathyroidism in the chronic renal insufficiency. 8. Intravenous infusion pharmacotherapy for secondary hyperparathyroidism.
- Secondary hyperparathyroidism in the chronic renal insufficiency. 9. Secondary hyperparathyroidism and PEIT.
- Secondary hyperparathyroidism in the chronic renal insufficiency.10. Surgical treatment of secondary hyperparathyroidism (parathyroid gland).
- Clinical pathway and pharmacist. (4). Know-how of plan and practice. Clinical pathway and team medical treatment in the internal medicine.
- Interaction between medicine and food. 16. I. Deleterious effects generated in the encounter of medicine and food and favorite food. 1. Food and favorite food make medicine poisonous. d). Medicine and sake. (1).
- Practical record of the pharmacological management. (4). Essential sheet and follow-up sheet. Orthopedics region. III.
- Interpretation of the test value necessary for the pharmacist work. 10. Test value, data analysis and measures relating to diabetes mellitus.
- Ketolide compounds. ABT-773 and HMR-3677.
2
- Dermatopathy caused by chemical substances. 17. 10. Metal allergy.
- Countermeasures for side effects in cancer chemotherapy. 1. Myelosuppression. Leukopenia and thrombocytopia.
- Countermeasures for side effects in cancer chemotherapy. 2. Cardiotoxicity.
- Countermeasures for side effects in cancer chemotherapy. 3. Nephrotoxicity.
- Countermeasures for side effects in cancer chemotherapy. 4. Depilation.
- Countermeasures for side effects in cancer chemotherapy. 5. Stomatitis.
- Countermeasures for side effects in cancer chemotherapy. 6. Nausea and vomiting.
- Countermeasures for side effects in cancer chemotherapy. 7. Diarrhea.
- Countermeasures for side effects in cancer chemotherapy. 8. Examination for prediction of side effects by assaying urinary 5-FDHU/5-FU.
- Clinical pass and pharmacists (5). Know-how of planning and practice. Practice of clinical pass in kidneys and urological regions.
- Interaction between drugs and foods 17. I. Deleterious effects generated in encounter of drugs and foods and favorite foods. 1. Foods and favorite foods make drug to poison. d) Drugs and sake (2).
- Practical records of pharmacological management (5). Essential sheet and follow-up sheet. Ophthalmological region I.
- Interpretation of test values necessary for pharmacists' business 11. Test value, data analysis and correspondence relating to bone, muscle and peritendinitis.
- Relationships between improvement of patients' QOL and pharmacists. 9 PART I. Hospital infection. Evaluation of usefulness of ointment for treatment of pigmentation.
- Relationships between improvement of patients' QOL and pharmacists. 9 PART II. Patient compliance instruction and ward activity. Preparation of thesaurus considering effective utilization of medication history. For improvement of patients' QOL as a result of education of clinical pharmacts and proper use of drugs.
- Brain protectives. Nicaraben, ebselen and edarabon.
3
- Features of drugs in treatment of osteoporosis.
- Features of drugs in treatment of osteoporosis 1. Estrogen preparations.
- Features of drugs in treatment of osteoporosis 2. Tibolone.
- Features of drugs in treatment of osteoporosis 3. Raloxifene hydrochloride.
- Features of drugs in treatment of osteoporosis 4. Calcitonin preparations.
- Features of drugs in treatment of osteoporosis 5. Ipriflavone.
- Features of drugs in treatment of osteoporosis 6. Bisphosphonates.
- Features of drugs in treatment of osteoporosis. Active vitamin D preparations.
- Features of drugs in treatment of osteoporosis. Vitamin K 2.
- Features of drugs in treatment of osteoporosis 9. Parathyroid hormone (PTH).
- Features of drugs in treatment of osteoporosis 10. Anabolic steroid hormone.
- Present state and future prospect of hemopoietic stroma transplantation.
- Present state and future prospect of hemopoietic stroma transplantation 1. Diversified features of hemopoietic stem cell transplantation and adaptation standard to various diseases.
- Present state and future prospect of hemopoietic stroma transplantation. Autologous peripheral blood stem cell transplantation.
- Present state and future prospect of hemopoietic stroma transplantation 3. Allogeneic peripheral blood stem cell transplantation.
- Present state and future prospect of hemopoietic stroma transplantation 4. Mini transplantation.
- Present state and future prospect of hematopoietic stroma transplantation 5. Cord blood transplantation.
- Present state and future prospect of hematopoietic stroma transplantation 6. Immunocytetherapy using dendritic cells.
- Clinical application of prokinetics. Approach from disease state 1 General remarks. Proper use of enterokinetic function improvement medicine.
- Clinical application of prokinetics. The approach from the disease state 2. NUD (non-ulcer dyspepsia). Mosapride.
- Clinical application of prokinetics. Approach from disease state 3. Gastro esophageal reflux disease (GERD). Outlines and significance of prokinetics.
- Clinical application of prokinetics. Approach from disease state 4. Management of postoperative digestive tract function. Disease state and treatment of postoperative paralytic ileus.
- Clinical application of prokinetics. Approach from disease state 5. Abnormal defecation (including IBS). Disease state and treatment of abnormal defecation.
- Clinical application of prokinetics. Approach from disease state 6. Elimination of H.pylori and enterokinetic dysfunction.
- Interaction of drugs and foods 18. I. Deleterious effects generated in the encounter of drugs and foods and favorite foods. 1. Foods and favorite foods change drugs to poisons. e) Side effect provided by after meals dose of drugs.
- Practical records of pharmaceutical management (6). Essential sheet and follow-up sheet. Ophthalmological region II.
- Interpretation of test value necessary for pharmacists' business 12. Test value and data analysis relating to abnormal thyroid function and countermeasure.
- Relationship between improvement of QOL of patients and pharmacists 10 PART I. Hospital formulary. Lapping method of 10% lidocaine gel for intractable peripheral neuralgia and therapeutic effect.
- Relationship between of improvement of QOL of patients and pharmacists 10 PART II. Patient compliance instruction and ward activity. Evaluation of ooral cryotherapy for stomatitis in cancer chemotherapy.
- Oxazolidinones. Linezolid.
4
- Dermatopathy caused by chemical substances. 12. Practice for elucidation of contact allergen (2). Allergic contact dermatitis caused by plastic products (glass parts).
- Recent topics on antimicrobial agents. 1. Review. Resistant microbes and antimicrobial agents in the twenty-first century.
- Recent topics on antimicrobial agents. Respiratory quinolone 2. Its adaptation and trend of development Including quinolones for intravenous injection.
- Recent topics on antimicrobial agents. 3. Present state on development of ketolide antimicrobial agent.
- Recent topics on antimicrobial agents. 4. Drug against VRE. 1) Linezolid.
- Recent topics on antimicrobial agents. 4. Drug against VRE. 2) Streptogramin antimicrobial agents.
- Trend of new treatments for DIC. 1. Trend of recent treatments for DIC.
- Trend of new treatments for DIC. 2. Fundamentals and clinic of heparan sulfate.
- Trend of new treatments for DIC. 3. Treatment strategy for DIC by heparin preparation.
- Trend of new treatments for DIC. 4. Trend on DIC treatment in foreign countries.
- New clinical evaluation standard and seriousness classification of allergic conjunctival diseases.
- Microbial production of anticancer drug etoposide from insecticidal active substance Deoxypodophyllotoxin (DPT). Studied from nature and learning from human.
- Development of troches of camostat mesylate for prevention of mouth mucosal failure in cancer chemotherapy.
- Clinical pass and pharmacists (6). Know-how of plan and practice. Intervention of pharmacists in clinical pass of surgical region.
- Interactions with drugs and foods. I. Deleterious effects generated in the encounter of drug, food and favorite food. 1. Food and favorite food convert the drug to poison. F) drugs and milk.
- Practical record of pharmacological management (7). Essential sheet and follow-up sheet. Ophthalmological region III.
- The interpretation of the test value necessary for the pharmacist business 13. Test value, data analysis and correspondence relating to pancreatic disease.
- Improvement in QOL of patients and relationship with pharmacists 11. PART I. Hospital preparation. Use experience of special hospital preparation, urinastatin vaginal suppository.
- Improvement in QOL of patients and relationship with pharmacists 11. PART II. Patient compliance instruction and ward activity. Relationship with cancer pain treatment in outpatient and evaluation.
- Latest information on injections necessary for pharmacists (5). Change upon mixing and critical point pH of theophylline kit pharmaceutical "theodrip".
5
- Dermatopathy caused by the chemical substances. (20). 13. Practice of the contact allergen elucidation. (3). Allergic contact dermatitis due to the textile products.
- Gene therapy and pharmaceutical sciences. 2. Potential gene therapy as the truly effective medical technology in the twenty-first century. Development of the new skeleton virus vector.
- Gene therapy and pharmaceutical sciences. 3. Development of high-functional ribozyme with the aim of gene therapy.
- Gene therapy and pharmaceutical sciences. 4. For practical application and further progress of medicine for gene therapy. Development of the new generation adenovirus vector.
- Gene therapy and pharmaceutical sciences. 5. Identification of the peptide which promotes the gene transfer and the functional analysis.
- Gene therapy and pharmaceutical sciences. 6. Cytospecific gene delivery.
- Gene therapy and pharmaceutical sciences. 7. DDS of gene medicine.
- Tackling the palliation care by the pharmacist.
- Formulation design of the sodium bicarbonate injection in the plastic ampul by the new barrier packaging on which the carbon dioxide indicator was printed.
- EBM (Evidence Based Medicine). 9. Atopic dermatitis.
- Clinical pathway and pharmacist. (7). Know-how of plan and practice. Clinical pathway in the Fukushima Medical Coll. medical school attachment hospital and pharmacist.
- Interaction of the drug and the food. 20. I. Deleterious effects caused in the encounter of the drug and food and favorite food. 1. Food and favorite food make the medicine poisonous. g). Medicine and tobacco.
- Practical recording of the pharmacological care. (8). Essential sheet and follow-up sheet. Ophthalmologic region. IV.
- Interpretation of the test value necessary for the pharmacist work. 14. Test value, data analysis related to cancer diagnosis and coping.
- QOL improvement of patient and involvement of pharmacist. 12. PART I. Hospital pharmaceutical preparation. Use experience of rebamipide gargling liquid for the purpose of the stomatitis onset prevention.
- QOL improvement of patient and intervention of pharmacist. 12. PART II. Guidance of drug administration and ward activity. Participation of the pharmacist in the Parkinson disease classroom.
- Latest injection information necessary for the pharmacist. (6). The pH characteristic curves of the various infusions and pH prediction during blending by the use of them.
- Monoclonal antibody. Rituximab.
6
- Dermatopathy caused by chemical substance [21] Detailed explanation 14. Practice on elucidation of contact allergen (4). Allergic contact dermatitis and urticaria caused by sundries.
- Features of carbapenem series antimicrobial agents and trend of development.
- Proper use of antibiotics for MRSA infection. General remarks. MRSA infection. Recent trends.
- Proper use of antibiotics for MRSA infection. Detailed explanation. 1. Proper use of vancomycin.
- Proper use of antibiotics for MRSA infection. Detailed explanation. 2. Proper use of teicoplanin.
- Proper use of antibiotics for MRSA infection. Detailed explanation. 3. Proper use of arbekacin.
- Proper use of antibiotics for MRSA infection. Detailed explanation. 4. Proper use of mupirocin.
- Treatment of hypertension patients having risk factor. Calcium antagonists. General remarks. Patients with hypertension having risk factor and treatment.
- Treatment of hypertension patients having risk factor. Calcium antagonists. Detailed explanation. 1. Hyperlipidemia and step-down treatment as risk factor.
- Treatment of hypertension patients having risk factor. Calcium antagonists. Detailed explanation. 2. Diabetes mellitus and step-down treatment as risk factor.
- Treatment of hypertension patients having risk factor. Calcium antagonists. Detailed explanation. 3. Cardiac hypertrophy and step-down treatment as risk factor.
- Treatment of hypertension patients having risk factor. Calcium antagonists. Detailed explanation. 4. Renal disturbance and step-down treatment as risk factor.
- Treatment of hypertension patients having risk factor. Calcium antagonists. Detailed explanation. 5. Aging and step-down treatment as risk factor.
- Treatment of hypertension patients having risk factor. Calcium antagonists. Short column. 1. Smoking and hypertension.
- Treatment of hypertension patients having risk factor. Calcium antagonists. Short column. 2. Hyperuricemia and hypertension.
- Treatment of hypertension patients having risk factor. Calcium antagonists. Short column. 3. Menopause and hypertension.
- Chinese medicine for prevention of adverse drug reactions caused by Western medicine. Reduction of adverse drug reactions of Western medicine by Chinese medicine observed in references.
- Test of upon mixing with tazobactam sodium and piperacillin sodium for injection.
- EBM is considered like this 10. Bronchial asthma.
- Risk managements. Activity of pharmacists in hospital (1). Risk management in the Gifu Univ. Hospital.
- Clinical pass and pharmacists (8). Know-how of plan and practice. Clinical pass and pharmacists in St. Luke's International Hospital. What is EBM in palliative care ?
- Interaction of eclipse and medicine 21. I. Deleterious effects generated in encounter of drug and food or favorite food. 1. Food and favorite food make drug to poison. h) Drug and cola beverage.
- Practical record of pharmacological management (9). Essential sheet and follow-up sheet. Diabetes mellitus region I.
- Improvement in patients' QOL and relation of pharmacists 13. PART I. Hospital formulary. Administration of semi-ordered TPN pharmaceutical preparation accompanied with nutrition support and its significance.
- Improvement in patients' QOL and relation of pharmacists 13. PART II. Patient compliance instruction and ward activity. Glaucoma classroom participated with hospital pharmacists.
8
- Dialysis patients and TDM.
- Psychosomatic ophthalmologic disorder.
- Sleep disorder. 1. General remarks. Definition and origin of sleep disorder.
- Sleep disorder. 2. Treatment of sleep disorder. Usage of hypnotics.
- Sleep disorder. 3. Drug induced sleep disorder.
- Sleep disorders. 4. Side effects and interactions of hypnotics.
- The sleep disorder. 5. A situation of prescription of drugs for treatment of insomnia in the Public Welfare Association Hospital in Aichi Prefecture.
- Clinical evaluation of fentanyl patch (KJK-4263) for cancer pain (1). Examinations on safety, effectiveness and pharmacokinetics.
- Clinical evaluation of fentanyl patch (KJK-4263) for cancer pain (2). Switching based on conversion table and examination in continuous administration.
- EBM is considered like this (12). Allergic rhinitis.
- Risk management Activities of pharmacists in hospital (3). Risk management of drugs in the Tokyo Medical Coll. Hospital.
- Clinical path and pharmacists (10). Know-how of plan and practice. Clinical path in the Okayama Univ. Medical School, Attached Hospital. Development with drug control guidance business.
- Interactions between drugs and foods. I. Deleterious effects generated by encounter of drugs and foods or favorite foods. 2. Drug converts foods and favorite foods to poison. a) drug and tuna.
- Practical records of pharmacological management (11). Essential sheet and follow-up sheet. Diabetes mellitus region III.
- Relationship between improvement in patients' QOL and pharmacists 15. PART I. Hospital preparations. Easily prepared hospital preparations, gummi drugs.
- Relationship between improvement in patients' QOL and pharmacists 15. PART II. Patient compliance instruction and ward activity. Involvement in cancer chemotherapy by pharmacists. The pre-treatment explanation of drugs and countermeasures for side effects in the gynaecologia ward.
- Latest information on injection necessary for pharmacists (7). Change upon mixing of Solumedrol and information on injection.
- HMG-CoA reductase inhibitor. Pitavastatin.
9
- 17. Dermatopathy caused by chemical substance 24. Contact dermatitis caused by clothing.
- Palliative care and role of pharmacists 1. General remarks Palliative care and role of pharmacists.
- Palliative care and role of pharmacists 2. Pharmacokinetics of morphine.
- Palliative care and role of pharmacists 3. Role of pharmacists in medical team Usage of morphine.
- Palliative care and role of pharmacists 4. Proper use of analgesic adjuvant in treatment of cancer pain and role of pharmacists.
- Palliative care and role of pharmacists 5. Palliative care and antianxiety agents.
- Palliative care and role of pharmacists 6. Side effects of morphine and countermeasure.
- Medical care for vertigo in the twenty-first century 1. Introduction Medical care for vertigo in the twenty-first century.
- Medical care for vertigo in the twenty-first century 2. Diagnosis of vertigo Historical changes of diagnosis and review of diagnostic criteria.
- Medical care for vertigo in the twenty-first century 3. Examination and differential diagnosis of vertigo 1). Test method of vertigo.
- Medical care for vertigo in the twenty-first century 3. Tests and differential diagnosis of vertigo 2). Usefulness of image diagnostic method in differential diagnosis.
- Medical care for vertigo in the twenty-first century 4. EMB in the pharmacotherapy of vertigo is considered like this.
- Medical care for vertigo in the twenty-first century 5. Medical care of vertigo Topics of foreign countries.
- Questionnairs of present state of chronic obstructive pulmonary disease (COPD) and QOL in the Tohoku region.
- Stability of various preparations of enalapril maleate in the non-packaging conditions.
- Studies on bacteriological disinfective effect of quick-dry rubbing type hand washing medicine "Gojo MHS".
- Contents of TDM training study in the Hospital Pharmacists' Association in Kagawa Prefecture and evaluation by questionnaires.
- EBM is considered like this 13.Otitis media.
- Risk management Activity of pharmacists in hospital 4. Risk management in the Showa Univ. Hospital Relation of pharmacists.
- Clinical path and pharmacists (11). Know-how of plan and practice. Clinical path in ophthalmologic region Practice of clinical path in cataract and questionnaires for patients.
- Interaction of foods and drugs 24. I. Deleterious effects generated in the encounter of drug and food and favorite food. The drug makes foods and favorite foods to posion. b) Drug and cheese.
- Practical record of pharmacological management (12). Essential sheet and follow-up sheet. Cardiovascular surgical region I.
10
- Dermatopathy caused by chemical substances 25. 18. Contact dermatitis caused by local anesthetic.
- Genetic polymorphism in drug metabolism and pharmacotherapy. Drug metabolizing enzyme and genetic polymorphism.
- Genetic polymorphism in drug metabolism and pharmacotherapy. 1. CYP1A2.
- Genetic polymorphism in drug metabolism and pharmacotherapy. 2. CYP2A6.
- Genetic polymorphism in drug metabolism and pharmacotherapy. 3. Genetic polymorphism of CYP3A molecular species.
- Genetic polymorphism in drug metabolism and pharmacotherapy. 4. CYP2C9.
- Genetic polymorphism in drug metabolism and pharmacotherapy. 5. CYP2C19.
- Genetic polymorphism in drug metabolism and pharmacotherapy. 6. CYP2D6.
- Genetic polymorphism in drug metabolism and pharmacotherapy. 7. Genetic polymorphism of human tissue allylamine N-acetyltransferase (NAT) and pharmacotherapy.
- Chronic pain and pharmacotherapy. 1. Concept of chronic pain and utility of pharmacotherapy.
- Chronic pain and pharmacotherapy. 2. Usefulness of analgesic adjuvant to chronic pain.
- Chronic pain and pharmacotherapy. 3. Application of narcotic drugs to chronic pain.
- Chronic pain and pharmacotherapy. 4. Application of non-narcotic analgesic drug to chronic pain.
- Chronic pain and pharmacotherapy. 5. Application of NMDA antagonist to chronic pain.
- Chronic pain and pharmacotherapy. 6. Application of Chinese medicine to chronic pain.
- Chronic pain and pharmacotherapy. 7. Pharmacotherapy of chronic pain noticed recently.
- Treatments and drugs for pathogenic parasites. 1. Nematodiasis (1). Ascariasis, trichuriasis, ankylostomiasis, strongyloidiasis and oxyuriasis.
- Treatments and drugs for pathogenic parasites. 2. Nematodiasis (2). Filariasis, gnathostomiasis and anisakiasis.
- Treatments and drugs for pathogenic parasites. Trematodiasis. Schistosomiasis, paragonimiasis, clonorchiasis, metagonimiasis and fascioliasis.
- Treatments and drugs for pathogenic parasites. 4. Cestodiasis Including hydatidosis.
- Treatments and drugs for pathogenic parasites. 5. Protozoal disease (1). Malaria, amebiasis, giardiasis, trypanosomiasis and leishmaniasis.
- Treatments and drugs for pathogenic parasites. 6. Protozoal disease (2). Toxoplasmosis, Pneumocystis carinii disease, trichomoniasis, Cryptosporidium disease, cyclospora infections, isospora infections.
- Denture and candida.
- Discussion on problems of drug information service Overlap of indication and initial symptom of important side effect.
- Utilization of TDM in safe switching from Sandemune to Neoral and patient compliance instruction to patients with ingestion contravention.
- Use condition of blood preparation in Attached Hospital, Medical School, Hirosaki Univ. Management of use record using bar code system.
- Fibromyalgia syndrome, markedly effected by serotonin-noradrenaline reuptake inhibitor (SNRI), a case report.
- Development of new ampule opening instrument With the aim of reducing contamination of glass piece particles.
- Present state of hosptal pharmacy and professional pharmacy cooperation in Chiba Prefecture and future prospect.
- Participation of pharmacists in disaster rescue From questionnaire results to the Red Cross Hospital.
- Ebidence based medicine is considered as like this. Chronic obstructive pulmonary disease.
- Risk management Ativity of pharmacists in hospital (5). Risk management in Attached Hospital, Medical School, the Kanazawa Univ. Patient safety risk management in pharmacotherapy.
- Interaction of drug and food 25. 1. Deleterious effects generated in the encounter of medicine and eclipse and favorite food. 2. Drug makes eclipse and favorite food to poison. c) Drug and coffee.
- Practical record of pharmacological management (13). Essential sheet and follow-up sheet. Cardiovascular surgery region II.
- Improvement in QOL of patients and relation of pharmacists 16. Part I. Hospital formulary. Preventive effect of allopurinol spray for stomatitis in cancer chemotherapy.
- Improvement in QOL of patients and relation of pharmacists 16. Part II. Patient compliance instruction and ward activity. Role of pharmacists in rounf of visits on infectious disease.
- Drugs for treatment of glaucoma. Bimatroprost
11
- Dermatopathy caused by chemical substance 26. 19. Fiberglass dermatitis.
- Management of pruritus. 1. Type and differentiation of pruritus.
- Management of pruritus. 2. Pruritus with internal disease.
- Management of pruritus. 3. Hemodialysis and pruritus.
- Management of pruritus. 4. Pruritus accompanied by dermatosis. Diagnosis and countermeasures. 1) Pruritus caused by inframmation. Urticaria, eczema and prurigo.
- Management of pruritus. 4. Pruritus accompnaied by dermatosis. Diagnosis and countermesures. 2) Pruritus caused by infection and insect. Trichophytia, candida, scabies and insect bite.
- Management of pruritus. 4. Pruritus accompanied by dermatosis. Diagnosis and countermeasures. 3) Drying of skin and pruritus. Atopic dermatitis and asteatosis.
- Management of pruritus. 5. Pharmacotherapy of pruritus.
- Forefront in proper use of antimicrobial agents. Based on present state of resistant microbes. 1 General review: Resistant microbes and antimicrobial agents.
- Forefront in proper use of antimicrobial agents. Based on present state of resistant microbes. 2. Infantile infection. 1) Guideline for medical care of purulent meningitis.
- Forefront in proper use of antimicrobial agents. Based on present state of resistant microbes. 2. Infantile infection. 2) Present state of resistant microbes in infantile respiratory infectious disease and proper use of antimicrobial agents.
- Forefront in proper use of antimicrobial agents. Based on present state of resistant microbes. 3. Respiratory infection 1). Present state and problem on treatment of community acquired pneumonia in the primary care.
- Forefront in proper use of antimicrobial agents. Based on present state of resistant microbes. 3. Respiratory infection. 2) Present state and treatment of resistant microbes in adult community acquired pneumonia.
- Forefront in proper use of antimicrobial agents. Based on present state of resistant microbes. 3. Respiratory infection. 3) Guideline for medical care of community acquired pneumonia and proper use of antimicrobial agent.
- Forefront in proper use of antimicrobial agents. Based on present state of resistant microbes. 4. Problems on treatment of acute otitis media.
- Evidence based medicine is considered like this 15. Pulmonary tuberculosis.
- Risk management. Activity of pharmacists in hospital (6). Risk management in Attached Hospital, the Kawasaki Medical School.
- Interaction of drug and food 26. I. Deleterious effects generated in the encounter of drug and food or favorite food. 2. Drug makes food and favorite food to poison. d) Drug and alcohol beverage.
- Practical record of pharmacological management (14). Essential sheet and follow-up sheet. Gastrointestinal medical region I.
- Improvement in patients' QOL and relationship with pharmacists 17. PART I. Hospital preparation. On usefulness of ketamine candy in preanesthetic medication of infant general anesthesia.
- Improvement in patients' QOL and relationship with pharmacists 17. PART II. Patient compliance instruction and ward activity. Evaluation of ward pharmacists' business by group control. Analysis from questionnairings.
- Fluid therapy question and answer (7).
- Pharmacological basic knowledge required in clinical field 1. Lactic acidosis.
12
- Clinic and treatment of the potassium dysbolism. 1. Basic knowledge of potassium. Metabolism of potassium and the action.
- Clinic and treatment of the potassium dysbolism. 2. Potassium and various diseases. 1). Hypertension and potassium.
- Clinic and treatment of potassium dysbolism. 2. Potassium and various diseases. 2). Heart failure and potassium.
- Clinic and treatment of potassium dysbolism. 2. Potassium and various diseases. 3). Kidney disease and potassium.
- Clinic and treatment of potassium dysbolism. 2. Potassium and various diseases. 4). Diabetes mellitus and potassium.
- Clinic and treatment of potassium dysbolism. 2. Potassium and various diseases. 5). Neuromuscular disease and potassium.
- Clinic and treatment of potassium dysbolism. 2. Potassium and various diseases. 6). Endocrine disease (adrenal gland) and potassium.
- Clinic and treatment of potassium dysbolism. 2. Potassium and various diseases. 7). Digestive system disease and potassium.
- Clinic and treatment of potassium dysbolism. 2. Potassium and various diseases. 8). Respiratory tract disease and potassium.
- Clinic and treatment of potassium dysbolism. 3. Potassium abnormality caused by the drug.
- Measurement of the concentration of milnasipran hydrochloride as the antidepressant in the body fluid by HPLC.
- Risk management. Activity of the pharmacist in the hospital. (7). The role of the pharmacist in the risk management in the Kitasato Univ. hospital.
- Interaction of drug with food. 27. I. Adverse effects caused in the encounter of drug and food and favorite food. 3. Accumulation of drug and food and favorite food. a). Drug and vitamin A.
- Practical record of the pharmacological management. (15). Essential sheet and follow-up sheet. Digestive system medical field. II.
- Improvement of patient QOL and participation of pharmacist. 18. PART I. Hospital preparation. Dosage form design and clinical application of oral mucosa adhesive cepharanthine gelation salve to oral lichen planus.
- Improvement of patient QOL and participation of pharmacist.18. PART II. Guidance of drug administration and ward activity. Relation of the pharmacist in the nonsmoking guidance and the usefulness.
- Pharmacological basic knowledge required in the clinic field. 2. Drug interaction between new quinolone drug and metal cation containing drug. Should the dose hour be really shifted?
| Copyright (c) 2006-2007 Japan Science and Technology Agency. All Rights Reserved. | |
